See more : Cineverse Corp. (IQ50.F) Income Statement Analysis – Financial Results
Complete financial analysis of Kraig Biocraft Laboratories, Inc. (KBLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kraig Biocraft Laboratories, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Dongguan Dingtong Precision Metal Co., Ltd. (688668.SS) Income Statement Analysis – Financial Results
- Sectra AB (publ) (0A0L.IL) Income Statement Analysis – Financial Results
- Hua Hsu Silicon Materials Co., Ltd. (6682.TWO) Income Statement Analysis – Financial Results
- PT Petrosea Tbk (PTRO.JK) Income Statement Analysis – Financial Results
- Esken Limited (ESKNF) Income Statement Analysis – Financial Results
Kraig Biocraft Laboratories, Inc. (KBLB)
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.62K | 97.32K | 31.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.62K | 28.10K | 3.68B | 13.09B | 14.79B | 11.52B | 10.56B | 16.97K | 15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.62K | -28.10K | -3.68B | -13.09B | -14.79B | -11.52B | -10.56B | 14.88K | -15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,868,283.05% | -10,850,924.48% | 46.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 237.87K | 176.43K | 197.75K | 88.47K | 223.05K | 148.07K | 258.89K | 397.14K | 432.01K | 439.54K | 489.43K | 465.29K | 250.60K | 141.31K | 69.80K | 33.08K | 177.02K | 164.91K |
| General & Administrative | 1.58M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 320.00K | 300.00K | 370.00K |
| Selling & Marketing | 797.41K | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.01K | -13.34K | -5.25K |
| SG&A | 2.38M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 312.99K | 286.66K | 364.75K |
| Other Expenses | 0.00 | 779.74B | 734.43B | 516.33B | 627.20B | -1.00 | 2.00 | -4.00 | -2.00 | -4.00 | -5.19M | 3.00K | 598.00 | 93.91K | 27.20K | 12.65K | 6.21K | -5.09K |
| Operating Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Cost & Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Interest Income | 0.00 | 1.72K | 5.36K | 386.62 | 6.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.00 | 192.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 375.10K | 609.13K | 660.42K | 386.62K | 294.35K | 228.95K | 177.11K | 139.43K | 101.55K | 69.28K | 0.00 | 45.71K | 0.00 | 52.38K | 41.81K | 7.24K | 122.00 | 654.00 |
| Depreciation & Amortization | 27.62K | 28.10K | 26.14K | 28.07K | 30.78K | 26.63K | 20.29K | 16.97K | 15.42K | 7.16K | 5.89K | 5.58K | 5.37K | 453.00 | 27.40K | -2.78K | 0.00 | 0.00 |
| EBITDA | -2.59M | -2.09M | -2.73M | -4.56M | -2.58M | -913.39K | -2.14M | -2.92M | -2.04M | -1.83M | -2.22M | -1.55M | -1.29M | -1.64M | -2.72M | -355.65K | -472.86K | -529.67K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -232.39% | -2,194.56% | -9,192.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.61M | -2.12M | -2.76M | -4.53M | -2.62M | -959.95K | -2.16M | -2.95M | -2.05M | -1.83M | -2.28M | -1.16M | -1.30M | -1.29M | -524.71K | -355.65K | -472.86K | -529.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -239.02% | -2,215.41% | -9,246.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -414.99K | -1.72M | -5.29M | -437.13K | -287.98K | -209.03K | -177.11K | -128.24K | -79.25K | -38.63K | -5.25M | -1.60M | 2.10K | -589.06K | -907.38K | -4.46K | -122.00 | -333.00 |
| Income Before Tax | -3.03M | -3.84M | -8.05M | -4.97M | -2.91M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.72M | 660.42K | 386.62K | 294.35K | 19.92K | 0.00 | 139.43K | 101.55K | 69.28K | 0.00 | 48.71K | 0.00 | 52.38K | 41.81K | 7.24K | 0.00 | 321.00 |
| Net Income | -3.03M | -5.56M | -8.71M | -5.36M | -3.20M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
| Weighted Avg Shares Out (Dil) | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
Kraig Biocraft Laboratories files for International Patents in Key Spider Silk Knock-in Knock-out Technology
Kraig Biocraft Laboratories and MtheMovement by Kings Group sign Exclusive Purchase and Sales Agreement for up to potentially $40 million
Kraig Biocraft Laboratories Secures Bridge Funding and Files to Become Fully Reporting Company
Source: https://incomestatements.info
Category: Stock Reports